Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Department of Neurology, Shahid Beheshti Universiry of Medical Science, Tehran, Iran.
Immunopharmacol Immunotoxicol. 2019 Dec;41(6):586-590. doi: 10.1080/08923973.2019.1672179. Epub 2019 Oct 8.
Multiple sclerosis (MS) is an autoimmune and chronic inflammatory disease of CNS. The α-L-guluronic acid (G2013) as novel NSAID with immunomodulatory effects has shown its positive effects in various investigations. Present research aimed to study the potency of G2013 on gene expression of TLR2, TLR4, MyD88, TNF-α and CD52 in PBMCs of MS patients under conditions. 24 blood samples from MS patients and healthy controls were considered for RT-PCR and flow cytometry techniques under two different doses of G2013. Our research indicated that this drug could significantly decrease the gene expression of TLR2, TLR4 and TNF-α compared to untreated group. Data demonstrated that the guluronic acid is able to modify the expression levels of TLR2, TLR4 and TNF-α genes to less than the pathogenic boarder line level, which it might be recommended for reducing the pathological process in multiple sclerosis.
多发性硬化症（MS）是一种中枢神经系统自身免疫性和慢性炎症性疾病。具有免疫调节作用的新型非甾体抗炎药 α-L-古洛糖醛酸（G2013）在各种研究中显示出了积极的效果。目前的研究旨在研究 G2013 对 MS 患者 PBMCs 中 TLR2、TLR4、MyD88、TNF-α 和 CD52 基因表达的影响。根据 G2013 的两种不同剂量，使用 RT-PCR 和流式细胞术技术对 24 份来自 MS 患者和健康对照者的血液样本进行了研究。我们的研究表明，与未处理组相比，该药物可显著降低 TLR2、TLR4 和 TNF-α 的基因表达。数据表明，古洛糖醛酸能够将 TLR2、TLR4 和 TNF-α 基因的表达水平降低到致病界限以下，这可能有助于减少多发性硬化症的病理过程。
